BIOMARKER:

EGFR exon 20 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : C3 ESMO 2022 - 3wk	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks afatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 mutation	Solid Tumor	EGFR exon 20 mutation	Solid Tumor	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	furmonertinib Sensitive: C2 – Inclusion Criteria furmonertinib Sensitive : C2	furmonertinib Sensitive: C2 – Inclusion Criteria furmonertinib Sensitive : C2
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3	icotinib Sensitive: C3 – Early Trials icotinib Sensitive : C3
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3